Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O7QQ
|
|||
| Former ID |
DNCL002471
|
|||
| Drug Name |
BIIB 022
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0] | Phase 1 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1] | ||
| Company |
Biogen Idec
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027382) | |||
| REF 2 | A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.